^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Chk2 inhibitor

    Related drugs:
    Apply
    Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02808650)
    Phase 1
    Children's Oncology Group
    Completed
    Last update posted :
    12/20/2023
    Initiation :
    02/27/2017
    Primary completion :
    12/31/2019
    Completion :
    03/31/2021
    AFP
    |
    TP53 mutation • TP53 deletion • TP53 expression
    |
    prexasertib (ACR-368)
    LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer (ExIST) (NCT04032080)
    Phase 2
    Baylor Research Institute
    Completed
    Last update posted :
    09/11/2023
    Initiation :
    09/05/2019
    Primary completion :
    06/01/2022
    Completion :
    11/26/2022
    ER
    |
    ER negative
    |
    prexasertib (ACR-368) • samotolisib (LY3023414)
    Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) (NCT04678102)
    Phase 1
    Seoul National University Hospital
    Recruiting
    Last update posted :
    06/26/2023
    Initiation :
    12/17/2020
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    HRD
    |
    HRD
    |
    cisplatin • PHI-101
    A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (NCT02873975)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    10/21/2022
    Initiation :
    10/12/2016
    Primary completion :
    09/30/2020
    Completion :
    07/01/2021
    BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation
    |
    prexasertib (ACR-368)
    A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer (NCT03414047)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    08/19/2022
    Initiation :
    04/10/2018
    Primary completion :
    06/03/2019
    Completion :
    10/03/2020
    BRCA1 • BRCA2 • BRCA
    |
    prexasertib (ACR-368)
    Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors (NCT03057145)
    Phase 1
    Geoffrey Shapiro, MD, PhD
    Completed
    Last update posted :
    09/02/2021
    Initiation :
    03/10/2017
    Primary completion :
    02/25/2020
    Completion :
    06/09/2021
    BRCA1 • BRCA2 • RAD51 • H2AX
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • prexasertib (ACR-368)
    Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML (PHI-101-001) (NCT04842370)
    Phase 1a/1b
    Seoul National University Hospital
    Recruiting
    Last update posted :
    04/20/2021
    Initiation :
    06/08/2020
    Primary completion :
    05/21/2022
    Completion :
    05/21/2022
    FLT3
    |
    FLT3-ITD mutation
    |
    PHI-101
    A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (NCT03495323)
    Phase 1
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    04/15/2021
    Initiation :
    05/16/2018
    Primary completion :
    02/01/2021
    Completion :
    02/01/2021
    PD-L1 • H2AX
    |
    PD-L1 expression
    |
    prexasertib (ACR-368) • lodapolimab (LY3300054)
    A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (NCT02124148)
    Phase 1b
    Eli Lilly and Company
    Completed
    Last update posted :
    04/01/2020
    Initiation :
    06/18/2014
    Primary completion :
    02/13/2020
    Completion :
    02/13/2020
    HER-2 • KRAS • ER • PIK3CA • PGR
    |
    HER-2 overexpression • PIK3CA mutation • KRAS wild-type • RAS wild-type • ER negative • PGR negative
    |
    Erbitux (cetuximab) • cisplatin • 5-fluorouracil • pemetrexed • prexasertib (ACR-368) • leucovorin calcium • samotolisib (LY3023414)
    A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (NCT02860780)
    Phase 1
    Eli Lilly and Company
    Completed
    Last update posted :
    12/14/2018
    Initiation :
    08/10/2016
    Primary completion :
    05/15/2017
    Completion :
    05/15/2017
    KRAS • BRAF
    |
    KRAS mutation • BRAF mutation
    |
    prexasertib (ACR-368) • ralimetinib (LY 2228820)